The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...

GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.

GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London Saturday, December 21, 2024, 17:30 ...

Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage ...

2024年12月18日，苏州宜联生物医药有限公司（以下简称“宜联生物医药”），一家处于临床阶段的生物科技公司，宣布其自主研发的抗体偶联药物YL201获得美国食品和药物管理局（FDA）授予的孤儿药资格认定（Orphan-drug Designation），用于治疗小细胞肺癌（SCLC）。YL201是一款基于宜联自主创新的TMALIN®技术平台的靶向B7H3的ADC药物。 目前，YL201项目正在全球 ...

In September 2024, Gilead announced a strategic partnership with Genesis Therapeutics, focusing on AI to discover and develop ...

眼下，据复宏汉霖执行董事、首席执行官朱俊博士形容，复宏汉霖进入了出海全球化2.0时代的“深水区”，接下来，在与各国家和地区的全球化共舞中，通过本地化能力的建设，致力于成为生物医药届出海的“领航者”。在中国的生物制药公司中，已经成立14年的复宏汉霖（2 ...